Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife extraction plant takes root in China

This article was originally published in The Tan Sheet

Executive Summary

As part of the multi-level marketer's "seed-to-feed" initiative, construction begins on an 80,000-square-foot botanical extraction facility in Hunan Province, China. Herbalife said Oct. 12 it intends to purchase botanicals from farmers in Changsha and process the raw materials - eventually about 8,000 metric tons annually - into extracts of guarana, chamomile, broccoli and other ingredients. The facility is a joint venture between Los Angeles-based Herbalife and NatSource Chemicals, a natural product extraction technology company, and is slated to open in the second half of 2011. Analysts estimate Herbalife's vertical integration could eventually enable it to manufacture 80 percent of its product portfolio (1"The Tan Sheet" Aug. 9, 2010)

You may also be interested in...

Sales & Earnings In Brief

Herbalife raises full-year guidance

Herbalife Rides Daily Consumption To Q2 Earnings Jump, Revised Guidance

Herbalife's daily consumption model is bearing substantial fruit across many of its 73 markets, driving record sales and prompting a significant earnings guidance hike

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts